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Abstract
Five X-linked severe combined immunodeficiency patients (SCID-X1) successfully treated with autologous bone marrow
stem cells infected ex vivo with an IL2RG-containing retrovirus subsequently developed T-cell leukemia and four contained
insertional mutations at LMO2. Genetic evidence also suggests a role for IL2RG in tumor formation, although this remains
controversial. Here, we show that the genes and signaling pathways deregulated in murine leukemias with retroviral
insertions at Lmo2 are similar to those deregulated in human leukemias with high LMO2 expression and are highly
predictive of the leukemias induced in SCID-X1 patients. We also provide additional evidence supporting the notion that
IL2RG and LMO2 cooperate in leukemia induction but are not sufficient and require additional cooperating mutations. The
highly concordant nature of the genetic events giving rise to mouse and human leukemias with mutations at Lmo2 are an
encouraging sign to those wanting to use mice to model human cancer and may help in designing safer methods for
retroviral gene therapy.
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Introduction
SCID-X1 patients are deficient in the common c chain of the
interleukin-2 receptor (IL2RG) [1]. In three SCID-X1 trials,
CD34
+ hematopoietic stem cells were cultured ex vivo and
transduced with a defective Moloney murine leukemia virus
(MuLV) expressing IL2RG and then transplanted back to the
patients. The possibility that retroviral gene therapy could induce
cancer through insertional mutagenesis had been widely discussed
but until these trials no cases had been reported. Among the five
leukemias that have occurred (four in the French and one in the
UK trial), four had insertional mutations at LIM domain Only 2
(LMO2) [2,3,4,5]. LMO2 is a T-cell oncogene [6], suggesting that
these leukemias resulted from insertional mutagenesis. SCID-X1 is
caused, in part, by a failure of T-cell production, and the infusion
of immature gene-corrected CD34
+ cells into SCID-X1 patients
favors the engraftment of the T-cell lineage over other lineages.
This could explain why T-cell leukemias predominate in these
patients. LMO2 is also expressed early in hematopoiesis [6,7]
which makes it a good target for insertional mutagenesis since
retroviruses like to preferentially integrate near the 59 end of
actively transcribed genes [8]. LMO2 is not the only T-cell
oncogene expressed during early hematopoiesis, however, indi-
cating there must be other reasons that favor mutagenesis of
LMO2. A murine T-cell leukemia with insertional mutations at
Lmo2 and Il2rg has also been reported [9]. The probability of
finding insertional mutations in both genes by chance in the same
leukemia is exceedingly small and has led to the suggestion that
Il2rg is a leukemia gene that cooperates with Lmo2. While IL2RG is
not overexpressed in SCID-X1 leukemias [3] or in the mouse
leukemia with an Il2rg insertion, subtle effects on its expression,
such as an inability to downregulate its expression during T cell
development, could be oncogenic [10].
Given the large number of IL2RG-infected cells transplanted into
each patient, there is ample chance that a patient would receive a
cell that contains an insertional mutation at LMO2 [9]. Why then
don’t all patients develop leukemia? The most likely explanation is
that other cooperating mutations are needed for leukemia to occur.
Consistent with this, leukemias take several years to develop and
contain mutations in other T-cell oncogenes [3,11].
PLoS Genetics | www.plosgenetics.org 1 May 2009 | Volume 5 | Issue 5 | e1000491To provide further insights into this problem we cloned and
sequenced the retroviral integrations from five murine leukemias
containing insertional mutations at Lmo2 using high-throughput
ligation-mediated PCR (LM-PCR)/sequencing method that
makes it possible to identify most of the insertionally mutated
genes in these leukemias. We then compared the microarray data
from human leukemias with upregulated LMO2 expression and
murine leukemias with insertional mutations at Lmo2. Our studies
show that murine leukemias are highly predictive of the leukemias
induced in SCID-X1 patients. They also support a model whereby
deregulated IL2RG and LMO2 expression cooperate to induce
leukemia but are not sufficient and require other cooperating
mutations.
Results
Five Murine Leukemias with Insertional Mutations at
Lmo2
The mouse Retroviral Tagged Cancer Gene Database
(RTCGD) (http://rtcgd.abcc.ncifcrf.gov) lists four AKXD murine
leukemias with insertional mutations at Lmo2 [9], in addition to the
AKXD leukemia analyzed previously which contains insertional
mutations at Lmo2 and Il2rg. All of the Lmo2 insertions are located
59 of coding exons 4–6 and are in the same general location as the
insertions identified at LMO2 in SCID-X1 patient leukemias and
the chromosomal breakpoints at LMO2 identified in sporadic
human T-ALL [3,12] (Figure 1A). Southern analysis showed these
insertions are clonal (Figure 1A, bottom left panel, data not shown)
and contain 2–4 clonal retroviral insertions each (Figure 1A,
bottom right panel), as would be expected if they harbor mutations
in Lmo2-cooperating genes.
Tumors 98-031 and 86-277 are T cell in origin [9]. Tumors
7105 and 7107 are also likely to be T cell as they have clonal Igh
and T-cell receptor Jb1 rearrangements (Figure 1B). The origin of
tumor 3095 is unclear. It was isolated from a mouse with
thymomegaly and lymphadenopathy and contains Igh but no T-
cell receptor gene rearrangements (Figure 1B, Jb2 not shown).
Tumors 3095 and 7105 showed aberrant B220 staining
(Figure 1C), which has been seen before in T-cell tumors from
Lmo2 transgenic mice [13] and in some human T-ALLs expressing
B-cell markers [14].
Large-Scale Cloning and Sequencing of Viral Integration
Sites
To identify genes that might cooperate with Lmo2 in tumor
induction we adapted an LM-PCR method to amplify the other
viral insertions present in the five AKXD leukemias [8,15].
Following nested PCR using virus-specific and adaptor-specific
primers, the amplified products were shotgun cloned. The inserts
were then sequenced and BLAST-searched against the mouse
genome and nearby candidate cancer genes identified (Table 1).
These data were then combined with a less robust data set
generated using inverse PCR (IPCR) [16]. This analysis identified
84 insertions in the five tumors (see Dataset S1). The percentage of
cells in a tumor that harbor an insertion can be estimated from the
number of shotgun clones isolated (Freq % in Dataset S1).
Insertions present in all tumor cells will be enriched during PCR
relative to insertions present in only a fraction of tumor cells and
will thus be overrepresented in the shotgun library.
Remarkably, 35 insertions are located at common insertion sites
(CISs), a highly significant result (Fisher’s exact test p=7.4610
239)
(Table 1). CISs are regions in the genome that are mutated by viral
insertion at a rate higher than predicted by random chance and
are thus likely to harbor a cancer gene [16]. Thirty-one of these
genes are also mutated in human cancer, another highly
significant result (Fisher’s exact test p=5.7610
237) (Table S1,
Dataset S1) [17]. This strongly suggests that some of these genes
are Lmo2-cooperating genes.
A Second Tumor with an Insertion at Il2rg
Surprisingly, tumor 7107 contains two Il2rg insertions (Table 1),
which was confirmed by conventional cloning and sequencing
(Figure 2A). Thus, 2 of the AKXD murine leukemias with
insertions at Lmo2 also contain insertions at Il2rg, a highly
significant result (p=1.34610
29, see Text S1 for calculation).
Likewise, tumor 7107 has two insertions at Irs2 (Figure 2B),
another highly significant result (p=1.16610
25, see Text S1 for
calculation). Il2rg and Irs2 are functionally linked in lymphoid
cells where it has been shown that Il2rg can promote the
phosphorylation of Irs2 by binding to and activating the tyrosine
kinase Jak3 [18], which may explain the co-selection for mutations
in these genes. To quantitate the Irs2 and Il2rg insertions, we
amplified one Lmo2 and one Il2rg insertion using insertion-site-
specific primers and real time PCR. The Irs2 insertion was present
at about one copy per cell (Figure 2B), indicating it is present in
every tumor cell. The other Irs2 insertion must therefore be in the
same tumor cell, either on the same or different chromosome. In
contrast, the Il2rg insertion was present at 0.5 copies per cell
(Figure 2B), suggesting it is present in only half the tumor cells of
this male mouse. We ruled out hyperploidy for the Irs2 locus and
also confirmed that the Il2rg gene was present at one copy per cell
(see Figure S4). The two Irs2 insertions must therefore have
occurred first and in the same tumor cell followed by the two Il2rg
insertions in different subpopulations of tumor cells. Similar to
what was reported previously [9], Il2rg is not misexpressed in
tumor 7107 (see Figure S3). Most of the genes that were
insertionally mutated in this tumor were also highly overexpressed
when compared to normal thymus control (Figure 2C). Since our
prior study, exons for the Med12 gene were annotated and are
shown to direct transcription in the opposite orientation to Il2rg
(see Figure 2A). All the tumors have insertions in the same
orientation to Med12 except tumor 98-031 and one of the
Author Summary
Twenty patients with X-linked severe combined immuno-
deficiency (SCID-X1) have been successfully treated by
gene therapy. Unfortunately, five of these patients have
developed T-cell leukemia two or more years after
receiving the therapeutic gene IL2RG on a retroviral vector.
The leukemias developed because the vector inserted
itself near cancer-causing genes and disrupted their
normal regulation. Remarkably, in four patients, the vector
inserted near a known T-cell oncogene, LMO2. We have
found that in mice, similar retroviruses cause T-cell
leukemias by inserting near Lmo2. We have found two
leukemias that have retroviral insertions near Lmo2 and
Il2rg in the same cell. The probability of these insertions
happening by chance is exceedingly small and these
results imply that these two genes are deregulated
together to induce leukemia. Our data show that Lmo2
and Il2rg cooperate but may not be sufficient for leukemia
development and additional mutations contribute to
leukemia development. We have also found cooperating
retroviral insertions in genes that are abnormally ex-
pressed in human T-cell leukemias. The mouse models
provide unique insight into the pathogenesis of T-cell
leukemia, and they are highly predictive of the leukemias
caused by SCID-X1 gene therapy.
Retroviral Insertional Mutagenesis
PLoS Genetics | www.plosgenetics.org 2 May 2009 | Volume 5 | Issue 5 | e1000491Figure 1. AKXD Leukemias have frequent clonal Lmo2 insertions of T-cell origin. A) The mouse Lmo2 gene is shown above the human
gene and the five independent viral insertions cloned from AKXD tumors indicated with red arrows. Tumor names are shown above the arrows. The
human LMO2 gene has six exons; gray exons are noncoding and yellow are coding. The bracket indicates chromosomal breakpoints in T-ALL
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not found to be up-regulated in the tumors and no spliced fusion
transcript between provirus and Med12 could be identified (see
Figure S3). It is conceivable that these insertions implicate Med12
in tumorigenesis and not Il2rg, however, the RTCGD contains
many common insertion sites in genes of the Il2rg pathway (e.g.
Il2ra, Il4ra, Il7, Jak1, Stat5a/5b).
Other Multiply Mutated Genes
Several other genes are also mutated more than once in the
Lmo2 tumors, indicating that they might also represent Lmo2-
cooperating genes. Two tumors have insertions in the leukemia
transcription factor oncogene Prdm16 (Figure 3A) but only the
insertion in tumor 7107 is clonal (Figure 3A, bottom left panel).
Quantitative RT-PCR/sequencing revealed marked upregulation
of a Prdm16 fusion transcript in tumor 7107 that initiates in the
viral 59LTR and splices to Prdm16 exon 2 (Figure 3A, bottom right
panel). This transcript is predicted to encode a truncated protein
similar to that expressed in human leukemias with PRDM16
mutations [19].
Remarkably, 3 tumors also have insertions in intron 2 of Mef2c
(Figure 3B, top panel), which is a transcription factor oncogene
that cooperates with Sox4 in leukemia induction [20]. All insertions
are in the same transcriptional direction as Sox4 and are clonal
(Figure 3B, bottom left panel). Quantitative RT-PCR/sequencing
revealed high expression of Mef2c fusion transcripts in these
tumors. The transcripts all initiated in the viral 59LTR and spliced
into the first coding exon of Mef2c (Figure 3B, bottom right panel),
similar to what is reported for other leukemias with Mef2c
insertions [20]. Tumor 7107 also showed high Mef2c expression
(Figure 3B, bottom right panel) and has an insertion located
390 kb upstream of Mef2c (Table 1). There is precedent for long-
range enhancer effects exerted by proviruses [21,22], potentially
accounting for the high Mef2c expression. Thus, 4 of 5 AKXD
tumors have insertions at or near Mef2c, strongly suggesting that
Mef2c is an Lmo2-cooperating oncogene. Consistent with this,
tumors 98-031, 7105 and 86-277 also had insertions near the
Mef2c-cooperating gene Sox4, although only the insertion in tumor
7105 was clonal (data not shown).
Finally, tumors 98-031 and 7105 have insertions in the 59 end of
the putative acetylglucosaminyltransferase gene, B3gntl1 (Table 1).
Very little is known about this gene so the significance of this result
is unclear.
Mutations in E2A-Related Genes
We also identified insertions in two E2A-related genes, Tcfe2a
(TCF3 in humans) and Tcf12 (Table 1), suggesting a role for E2A-
related genes in the Lmo2 tumors (p=0.008). TCF3 is translocated
to a number of fusion partners in pre- and pro-B-ALL [23], while
TCF12 is fused to NR4A3 in extraskeletal mixoid chondrosarcoma
[24]. The Tcf12 insertion is located in intron 5 and is in the same
transcriptional orientation as Tcf12 (Figure 4A). 59RACE showed
that it induces a fusion transcript, which initiates in the 59LTR and
splices to Tcf12 exon 9 (Figure 4B). The first ATG is located in
exon 9 and is in-frame with Tcf12 coding sequences. Assuming this
is the preferred translational start site, the predicted polypeptide
would lack 219 residues from the amino terminus, which was
confirmed by in vitro transcription and translation studies
(Figure 4C, left panel). The major polypeptide migrated at
55 kDa, similar to its predicted mass of 52 kDa. A faint 50-kDa
band was also observed. Both proteins were immunoprecipitated
with a rabbit polyclonal antibody specific to Tcf12, confirming
they are Tcf12-derived (Figure 4C, right panel). The smaller
protein could arise from an alternate translational initiation site or
be due to protein degradation.
Tcf12 and Tcfe2a are class I bHLH transcription factors. The
amino terminus of Tcf12 encodes two transactivation domains,
AD1 and AD2. AD1 is similar to AD1 of the related E2A proteins,
which has been shown to have greater potency in transactivation
than AD2 [25]. While there are no mutagenesis data on the
homologous domains of Tcf12, the truncated Tcf12 transcript
expressed in tumor 3095 would lack the AD1 domain but have an
intact AD2 domain, which could result in attenuated transactiva-
tion.
Microarray analysis showed there was considerable differential
expression of E2A target transcripts when the five tumors were
compared to normal thymus [26] (Figure 4D). Similar, but
somewhat less, differential expression, was observed when the
tumors were compared with tumor 7065, which has an insertion at
Notch1 (Figure 4D). With the exception of Gfi1b, targets activated
by E2A are poorly expressed as expected if E2A signaling is
attenuated. Conversely, Gm2a, which is repressed by E2A, was
highly expressed. These results provide further evidence that the
E2A pathway is attenuated in tumors with mutations at Lmo2.
Microarray expression analysis also showed that these tumors
express Tal1 as well as the other experimentally verified Lmo2
binding partners, consistent with the involvement of Lmo2 in these
tumors (Figure S1).
Insertionally Mutated Genes Are Highly Expressed in
Human T-ALL with High LMO2 Expression
To provide additional evidence that the genes insertionally
mutated in murine Lmo2 tumors are causally associated with
human T-ALL, we examined the raw data from three large
human T-ALL microarray data sets (total of 118 cases) [27,28,29]
and asked whether any of the murine genes are deregulated in
human T-ALL with high LMO2 expression. We separated the
human T-ALL cases into LMO2-high and LMO2-low expression
classes and performed clustering analysis to identify the genes
differentially expressed in the LMO2-high class (p,0.001 signif-
icance level). The data sets were remarkably consistent in the genes
that were upregulated in the LMO2-high class, despite different
array platforms and patient heterogeneity. When genes that were
consistently deregulated in the LMO2-high class were queried
against the RTCGD, a statistically significant number were
located at CISs or are insertionally mutated in murine tumors
involving 11p13. LMO2 was also insertionally activated in four SCID-X gene therapy patients. Only data for patients 4 and 5 from the French trial are
available. Red arrows indicate the site and orientation of gene therapy vector insertion. The BamHI sites used for Southern analysis and the positions
of probes (A, B, C) are shown. Molecular weight markers are shown to the left of the blots. Retroviral insertions introduce BamHI sites and show a
rearranged band indicated with red asterisks. The germline bands were verified by Southern analysis of genomic DNA from brain and indicated G.
The blot on the right was done using a probe (p15E) specific to the ecotropic envelope. B) Southern blots using probes specific for immunoglobulin
heavy chain Igh and T-cell receptor Jb1 genes are shown with molecular weight markers. Igh shows a 6 kb germline band and the Jb1 blot shows a
5.8 kb germline band. The other bands indicate rearrangements that confirm the monoclonality of the tumors. C) Immunohistochemistry of Lmo2-
clonal tumors 3095, 7105, and 7107 is shown. The H&E stain shows homogeneous appearing blast cells that have infiltrated and effaced the lymph
nodes. All three tumors show mild CD3 staining and mild (3095) to moderate (7105) B220 staining.
doi:10.1371/journal.pgen.1000491.g001
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much higher than expected by chance (Figure S2; Ferrando et al,
p=1.1610
23 and Yeoh et al, p=1.1610
23; Chiaretti et al,
p=4.1610
26).
Remarkably, MEF2C was overexpressed in the LMO2-high
group in all three T-ALL data sets (Figure 5A). This is extremely
unlikely to have occurred by chance and further confirms the role
of this gene in human T-ALL. Likewise, LAPTM5, which is the site
of an insertion in tumor 7107, was identified in all three data sets,
while NMYC, an insertion site in tumor 7105, was identified in two
microarray data sets (Figure 5A). STAT5A was found in two data
sets. Stat5a is not insertionally mutated in the murine tumors but it
is a validated leukemia gene and functions in the same signaling
pathway as IL2RG. Most of the genes that clustered with the
Table 1. Annotated common insertion sites found by LM-PCR/shotgun cloning of AKXD Lmo2 tumors.
Tumor Gene symbol Protein function Location Distance Dir
Tumor 3095
Lmo2 Transcriptional regulator 5 prime 36.35 kb inv
Ccnd3 Cell cycle regulator 5 prime 57.392 kb inv
Mef2c Transcription factor intron 2 not disrupt CDS same
St3gal6 Glycosyltransferase intron 2 not disrupt CDS inv
Tcf12 Transcription factor intron 5 disrupt CDS same
Tumor 98-031
Lmo2 Transcription factor 5 prime 69.237 kb inv
Il2rg Cytokine receptor 5 prime 6.244 kb same
B3gntl1 Glycosyltransferase 5 prime 0.739 kb same
Mef2c Transcription factor intron 2 not disrupt CDS same
Bmi1 Transcription factor 5 prime 67.614 kb inv
Rap1gds1 G-protein regulator intron 2 disrupt CDS inv
Sox4 Transcription factor exon 1 not disrupt CDS same
Tumor 7105
Lmo2 Transcriptional regulator 5 prime 68.071 kb inv
B3gntl1 Glycosyltransferase 5 prime 13.488 kb same
Me3 Malic enzyme intron 7 disrupt CDS inv
Mef2c Transcription factor intron 2 not disrupt CDS same
Nmyc Transcription factor 3 prime 815 kb same
Pou2f2 Transcription factor intron 1 disrupt CDS inv
Prdm16 Transcriptional regulator intron 1 disrupt CDS same
Sox4 Transcription factor exon 1 not disrupt CDS same
Tcfe2a Transcription factor 5 prime 2.717 kb inv
Tumor 7107
Lmo2 Transcriptional regulator 5 prime 68.387 kb inv
Il2rg Cytokine receptor 5 prime 6.396 kb inv
Il2rg Cytokine receptor 5 prime 6.759 kb inv
Irs2 Adaptor for signal transduction intron 1 disrupt CDS same
Irs2 Adaptor for signal transduction intron 1 disrupt CDS same
Mef2c Transcription factor 5 prime 389.868 inv
Ccnd1 Cell cycle regulator 5 prime 110.927 kb inv
Fgfr3 Growth factor receptor 3 prime 8.94 kb inv
Laptm5 Lysosomal protein intron 1 disrupt CDS inv
Prdm16 Transcriptional regulator intron 1 disrupt CDS same
Rere Transcriptional regulator N/D N/D
Tumor 86-277
Lmo2 Transcription factor 5 prime 0.955 kb inv
Fli1 Transcription factor intron 1 disrupt CDS same
Fnbp4 Cytoskeletal protein 5 prime 0.443 kb inv
Sox4 Transcription factor 5 prime 38.481 kb inv
Genes nearest the sites are shown below the tumor names. Predicted or known protein function and the distance and orientation of the insertions with respect to the
nearby gene are shown. All these insertions are CIS in the RTCGD (see text).
doi:10.1371/journal.pgen.1000491.t001
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and some showed differential expression in comparison to normal
thymus or tumor 7065 (Figure 5B).
Multiple RAP1 pathway genes also clustered with the LMO2-
high group, including RAP1B, RAP1A and RAPGEF5. None are
insertionally mutated in AKXD tumors, however, Rap1gds1 is
insertionally mutated in tumor 98-031 and is the site of a recurrent
chromosomal translocation in human T-ALL [30]. Rap1gds1
stimulates the exchange of GTP for GDP on Rap1 and is an
activator of the Rap1 pathway. Upregulation of Rap1gds1 could
therefore produce the same effect as upregulating RAP1B, RAP1A
or RAPGEF5. Pathway analysis on genes shared in at least two
microarray datasets (mouse and human combined) also suggested
a role for cytokine signaling in tumor development (see Figure S5).
Discussion
To provide a better mechanistic understanding of SCID-X1
patient leukemias, we have analyzed five murine T-ALLs with
insertional mutations at Lmo2. In each case these insertions are
clonal. Therefore, they must have occurred early in tumor
induction, similar to four of the five cases of gene therapy-induced
leukemias. Transcriptional profiles of these T-ALLs showed high
expression of the Tal1 and Lyl1 oncogenes as well as other Lmo2-
binding partners such as Gata1 and Gata2. TAL1 and LYL1 are
class II bHLH transcription factors that are frequently overex-
pressed along with LMO2 in human T-ALLs [27,31]. Consistent
with this, patient #4, who developed leukemia in the French trial,
and patient #8, who developed leukemia in the English trial,
showed rearrangement of the SIL-TAL1 loci along with insertional
activation of LMO2 [3,5,32].
Murine T-ALLs with Lmo2 insertions also showed consistent
downregulation of genes activated by E2A and upregulation of
genes repressed by E2A, consistent with previous studies
suggesting that Lmo2 redirects E2A activity by binding it through
its partner proteins, Tal1 or Lyl1 [6]. Genes that are activated by
the Lmo2/Tal1/E2A/Gata1-containing complex in normal
erythrocyte development were also overexpressed in one murine
T-ALL with high Gata1 expression. These findings suggest that
murine T-ALLs with Lmo2 insertions resemble human T-ALLs
that are initiated by LMO2 deregulation.
Our high throughput insertion site analysis identified additional
disease-related genes that are likely to cooperate with Lmo2 in
leukemia induction. We identified a second tumor (7107), in
addition to tumor (98-031) described previously [9] that has an
Figure 2. Tumor 7107 has two independent insertions in Il2rg
and Irs2 genes. A) LM-PCR identified two independent insertions in
tumor 7107, 59 of the eight coding exons of the Il2rg gene. The two viral
chromosomal junctions were independently cloned and sequenced.
The insertions were 396 bp apart and should be present in the same
clone if they occurred on the same chromosome. Partial sequence for
clone 23-10 shows the region of identity with clone 23-1 (green). For
clone 23-1, we found viral sequence 59 of this region instead of
chromosome X genomic sequence. B) Two insertions in the Irs2 gene
were also isolated from the same tumor. Primers were designed for one
allelic insertion for Irs2 and Il2rg and real time PCR performed on the
genomic DNA. Primers for a chromosome X sequence were used as
reference and show a copy number of 1 for this male mouse. As shown,
each insertion comprises about 50% of total tumor genomic DNA. We
ruled out polyploidy for Irs2 and Il2rg genes (see Figure S4). C) Panel
shows a heat map of gene expression data using the mouse Affymetrix
array. The expression of genes near high frequency insertions cloned
from 7107 is shown with respect to normal thymus. Log2 intensity scale
is shown under the heat map.
doi:10.1371/journal.pgen.1000491.g002
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that occurred independently suggesting strong selection for Il2rg
deregulation in Lmo2-initiated T-ALL. In addition, tumor (7065)
has insertions in Notch1 and Il2rg, suggesting that Il2rg might be
able to cooperate with other T-cell oncogenes (i.e. Notch1)i n
leukemia induction.
The newly identified insertions are also close to or within the
Med12 gene. Similar to Il2rg, this gene is not activated or
downregulated by the insertions. We favor Il2rg as the retroviral
target since the RTCGD is replete with common insertions in
cytokine receptors that act in the exact same pathway as Il2rg.
More recently, we have found Il2rb is a common insertion site in a
retroviral insertional mutagenesis screen in Lmo2 transgenic mice
(U.P. Dave ´, unpublished observation). Other Il2rg binding
partners, Il7ra and Jak1, were insertionally activated in the same
screen which has not reached saturation. While still somewhat
controversial, two studies provide additional evidence that Il2rg
can function as an oncogene under some circumstances [33,34]. A
statistically significant enrichment of Il2rg-dependent cytokine
pathways in murine T-ALLs containing Lmo2 insertions and
human LMO2-overexpressing T-ALLs was also observed by
Ingenuity pathway analysis (see Figure S5). A role for these
pathways in T-ALL is further supported by studies showing that
cytokines, which depend on Il2rg for signaling can induce T-ALL
in transgenic mice, and by the murine T-ALL with two Il2rg and
two Irs2 insertions. This murine T-ALL is significant since Irs2
encodes a protein adaptor that is phosphorylated by JAK3 tyrosine
kinase in response to cytokine ligation by Il2rg and its
heterodimeric partners such as Il7ra, Il4ra and Il9ra [18,35].
The occurrence of leukemias in the SCID-X1 gene therapy trials
also lends compelling support to the notion that IL2RG is
oncogenic and a cooperating ‘‘hit’’ with LMO2.
Il2rg expression was not upregulated in any of these three
tumors but there is precedent for cancer genes being dysregulated
without gross overexpression or at specific developmental stages
[36,37,38]. Similarly, the IL2RG transgene was not overexpressed
Figure 3. Prdm16 and Mef2c genes are frequently insertionally mutated in AKXD Lmo2 tumors. A) The Prdm16 gene was targeted in
tumors 7105 and 7107. Coding exons are in yellow. Tumor 7107 had a clonal insertion as shown by the Southern blot. G shows germline bands and a
red asterisk shows the rearrangement. The graph shows quantitative RT-PCR analysis for Prdm16. Real time PCR was normalized to expression in
normal thymus. Tumor 7107 had a viral fusion transcript spliced from the 59LTR to exon 2. The transcript from tumor 7105 was not recovered from
the RNA since the insertion was subclonal. B) The Mef2c gene was insertionally activated in three tumors, 3095, 7105, and 98031. Southern blot using
BglII-digested genomic DNA using the probe (thick line) shows all insertions were clonal and early in tumorigenesis. Quantitative RT-PCR shows the
up-regulation of Mef2c.
doi:10.1371/journal.pgen.1000491.g003
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[5,11]. We theorize that a gene is less able to be silenced if there is
a nearby retroviral insertion. Enforced expression of Il2rg has been
shown to cause T-cell leukemias without gross overexpression
[33,39]. In the study by Woods et al, they specifically remark that
transgene levels in thymic lymphomas were comparable to Il2rg
expression levels seen in developing thymi [34]. Another
compelling possibility is that Il2rg is misexpressed in a target cell
population where Il2rg is not normally found such as a cell more
primitive than a thymocyte precursor. The study by Shou et al
presents an alternate hypothesis that the SCID-X1 background is
required for leukemia development perhaps due to altered
numbers of hematopoietic precursors or stem cells [33]. It may
be that the lack of Il2rg creates a differentiation block that expands
a cell type that is susceptible to transformation. Recurrent
insertions in genes that are also CIS in the RTCGD were
identified by Shou et al but Lmo2 was not one of them. The tumors
were not analyzed for Lmo2 overexpression or for Notch1 activating
mutations. Our data suggests that leukemia requires many ‘‘hits’’
and in their model somatic mutation in cooperating oncogenes or
tumor suppressor genes may be more likely than insertional
mutation since their vector was replication-defective.
Retroviral insertion site profiles have recently been published
for the French and English cohorts of SCID-X gene therapy
patients (n=14) [4,5,11,40]. Presently, there is no statistical
difference between the incidence of leukemia in the French (4 of
10) and English patients (1 of 10) and with long term follow-up,
even the insertion site profiles may be quite similar in the two
studies. Comparison of the insertion sites identified in the French
patients with those in RTCGD showed there was a statistically
Figure 4. Tcf12 insertion creates a truncated protein. A) Top panel shows the mouse Tcf12 gene with arrows indicating the ubiquitous
promoter and an alternate promoter found in thymus (Alt). Yellow exons are coding and the red arrow indicates the retroviral insertion cloned from
tumor 3095. B) Panel shows the sequence of the viral fusion transcript cloned by RT-PCR from this tumor. 59RACE showed transcription was initiated
in the viral 59LTR and spliced into exon 9. The partial sequence of the viral fusion transcript is shown. Red indicates viral sequences, LTR and 59 of gag.
Yellow denotes the start of exon 9 of Tcf12. The first ATG codon (blue) is in frame with the rest of Tcf12. C) Panel shows two SDS-PAGE blots: left panel
shows in vitro transcription and translation of the cloned viral fusion cDNA with radiolabeled
35S-methionine. A strong band at 55 kDa appears as
well a weaker band at 50 kDa. The in vitro translated proteins were derived from Tcf12 since they were immunoprecipitated with an antibody specific
to the protein’s COOH-terminus (right panel). D) This heat map shows microarray analysis of the Lmo2-clonal tumors with selected E2A targets. The
genes shown are normally up-regulated by E2A except for Gm2a which is repressed. Included in the comparison is tumor 7065 which had a clonal
insertion in Notch1 and no up-regulation of Lmo2.
doi:10.1371/journal.pgen.1000491.g004
Retroviral Insertional Mutagenesis
PLoS Genetics | www.plosgenetics.org 8 May 2009 | Volume 5 | Issue 5 | e1000491Figure 5. Human microarray studies show consistent high-level expression of genes and pathways insertionally mutated in AKXD
Lmo2 tumors. A) Genes selectively expressed in LMO2-overexpressing patients from three human microarray analyses are shown. Below the first
author citations are shown the number of patients in each study. The genes shown in red are retroviral insertions in the mouse Lmo2-clonal tumors.
B) Select genes that were expressed in the LMO2-high class of patients were probed in the mouse tumors and are shown in the heat map. Several of
these genes (e.g. Mef2c, Hhex, Syk, Lyn, Mycn) are differentially expressed in the mouse tumors in comparison to normal thymus and tumor 7065.
doi:10.1371/journal.pgen.1000491.g005
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located at CISs in murine hematopoietic tumors (63/554, Fisher’s
exact test, p=4.5610
222). Remarkably, patient #10 of the French
trial showed clonal insertions in LMO2 and BMI1; these two
insertions were observed in tumor 98-031, underscoring the
predictive power of our mouse models [11].
In designing safer vectors for transduction, it will be important to
consider self-inactivating LTRs and perhaps lentiviral backbones,
which have different insertion site preferences than gamma-
retroviruses, which may carry a lower risk of insertional mutation
[41]. With the high transduction efficiencies achieved in these gene
therapy trials, onecould also seeclonalexpansion incases wherethe
transduced gene is not oncogenic. This, in fact, happened recently
in two chronic granulomatous disease patients treated by retroviral
gene therapy [42]. In both patients, a clonal expansion of the
myeloid compartment was observed that began 3 to 5 months post-
transplant. Clonal expansion was associated with insertional
mutation of just three genes: MDS/EVI1, PRDM16,o rSETBP1.
Astonishingly, in the mouse, insertional mutation of these same
genes has been associated with immortalization of early hemato-
poietic progenitor and/or myeloid progenitor cells [19]. Insertional
mutations in these genes may have been selected in transplant
patients dueto their effects on increased self-renewal or engraftment
potential. Prdm16 is also insertionally mutated in two of the murine
T-ALLs with Lmo2 insertions so this gene’s involvement in tumor
induction might not be limited to the myeloid lineage.
Materials and Methods
Ethics Statement
Mice were aged in SPF facilities according to approved IACUC
protocols at NCI-Frederick.
Mice, Tumors, and DNA/RNA Preparation
Various AKXD strains were developed at the Jackson
Laboratory. These are recombinant inbreds that have a high
spontaneous rate of leukemia or lymphoma onset due to the
presence of an endogenous retrovirus [43,44]. The mice are
viremic from birth and perhaps in utero and develop disease at
various latencies, usually over six months of age. Murine leukemia
viruses are not introduced. The mice are simply aged in SPF
facility until the onset of disease. At the first appearance of
morbidity, mice were sacrificed and gross necropsies performed.
Organomegaly and abnormal features were noted and lymphoid
and hematopoietic tissue was harvested and flash frozen in liquid
nitrogen. Tissue was also fixed in formalin for immunohistochem-
istry. Frozen tissue was used in the preparation of high molecular
weight DNA and whole RNA as previously described [45].
Tumor Histochemistry and Southern Analysis
Tumor genomic DNA was restriction digested and loaded on to
agarose gels for overnight runs. The gels were transferred as
described to Nitrocellulose (Amersham) [44]. Membranes were
baked and UV-crosslinked. They were hybridized with
32P-labeled
probes and exposed to film. For quantification, blots were exposed
to phosphorimager plates and a Fuji phosphorimager used for
quantitation. Details on probes used are available upon request.
Paraffin-embedded tumors were sectioned and probed with a
labeled BAC encompassing the mouse Irs2 gene. Labeling and
FISH were performed by manufacturer’s protocol (Vysis).
Retroviral Insertion Site Cloning and Analysis
Inverse PCR was performed as previously described [46]. For
LM-PCR, tumor genomic DNA (1 mg) was digested overnight
with NlaIII or MseI. The internal amplicon was eliminated by a
SpeI digest. DNA was column purified (Amersham GFX) and
ligated to a double stranded adaptor. This adaptor was made by
annealing sense and antisense strands with NlaIII or MseI
compatible overhangs as previously described [45]. The ligation
mix was column purified (Qiagen) and then used for nested PCR.
The PCR products were column purified and then ligated into
pGEMT-Easy (Promega) plasmids and plated. Ninety six colonies
were picked and miniprep DNA prepared using Whatman Ultra
filters. Miniprep DNA was sequenced in 96 well format
(Functional Biosciences) and files were analyzed in FASTA
format. Valid sequences contained 39LTR and adaptor at either
end were then batch BLASTed against the mouse genome.
Annotated insertions are posted at http://rtcgd.abcc.ncifcrf.gov.
Insertions were confirmed by either Southern analysis or PCR
using gene-specific primers in the vicinity of insertions. For tumor
7107, gene specific primers corresponding to Il2rg and Irs2 were
used in real time PCR (Biorad MyIQ) to confirm biclonality. For
tumor 3095, virus-specific and Tcf12-specific primers were used in
RT-PCR to generate cDNA for the viral-fusion transcript.
59RACE was done using SMART Race kit (BD Biosciences) to
verify that the transcriptional start site was in the virus. The full
length cDNA was sequenced from both ends and TA-cloned into
pGEMT-Easy (Promega); NotI digest released this cDNA for
subcloning into pcDNA3.1 (Invitrogen). Orientation was verified
and in vitro transcription and translation was performed using the
TnT kit (Promega) with
35S-labeled methionine (Amersham). In
vitro translated Tcf123095RIS was resuspended in RIPA buffer
and immunoprecipitated using antibody against the COOH-
terminus of Tcf12 (sc-357, Santa Cruz Biotechnology).
Gene Expression Analyses of Mouse Tumors
Tumors were homogenized in Trizol reagent (Sigma) and whole
RNA was isolated by manufacturer’s protocol. First strand cDNA
was synthesized using oligo-dT primer and Superscript II or III
reverse transcriptase enzymes (Invitrogen). Primers used for RT-
PCR are available upon request. For real time PCR, we used
Biorad’s MyIQ or ABI 7700 machines with either Sybr green
master mixes (Biorad) or Taqman probes (Applied Biosystems).
Probe assays used are available upon request and were validated
by Applied Biosystems. RNA was processed for hybridization to
the Affymetrix chips according to standard protocols (see Text S1).
Microarray Analyses of Human T-ALL Datasets
Microarray analysis was performed with BRB-ArrayTools
(version 3.2.3) developed by Biometric Research Branch at the
National Cancer Institute. LMO2- positive and LMO2-negative
tumors were compared by using univariate significance tests at the
significance level of 0.001. The maximum false discovery
proportions were restricted to 0.1 using multivariate permutation
tests. As for the criteria of LMO2-positive and LMO2-negative
tumors, there was no clear cut-off level for classifying a sample as
having either high or low expression. We used artificial cut-off
values to classify tumors into two groups. At first, we identified the
median value of LMO2 expression signals as an initial indicator for
the classification, and then we removed the marginal cases from
the comparisons. For example, in the case of St Jude’s data, we
classified tumors with LMO2 signal.2000 as LMO2-positive group
(13 cases), tumors with LMO2 signal,1000 as LMO2-negative
group (14 cases).
Statistical comparison between tumor classes was done using the
‘‘BRB Array Tools’’ software (http://linus.nci.nih.gov/BRB-
ArrayTools.html). We collated CEL file format of Affymetrix data
by using the ‘RMA’ method [47] of the ‘affy’ package from
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that were differentially expressed among the two classes, we used a
random-variance t-test. The random-variance t-test is an im-
provement over the standard separate t-test as it permits sharing
information among genes about within-class variation without
assuming that all genes have the same variance [48]. Genes were
considered statistically significant if their p values were less than
0.001. A stringent significance threshold was used to limit the
number of false positive findings. We also performed a global test
of whether the expression profiles differed between the classes by
permuting the labels of which arrays corresponded to which
classes. For each permutation, the p values were re-computed and
the number of genes significant at the 0.001 level was noted. The
proportion of the permutations that gave at least as many
significant genes as with the actual data was the significance level
of the global test. We performed cluster analysis of genes and
produced a heat map image to represent the over- and under-
expression of each gene in each sample. We used quantile data
ranges to ensure the even presence of all available colors on the
map.
For comparison of mouse and human datasets, we used Fisher’s
exact test, binomial distribution and Chi-square tests to generate p
values. Please see Text S1 regarding specific statistical questions
analyzed.
Supporting Information
Figure S1 AKXD Lmo2 tumors co-express Tal1. A) quantitative
RT-PCR shows Lmo2 and Tal1 are overexpressed in the tumors
with respect to normal thymus. To the right are two heat maps
from microarray expression data. B) This panel shows T-cell
leukemia transcription factors and their expression in the Lmo2-
clonal tumors. RNA from normal thymus and tumor 7065, which
has a clonal, activating mutation in Notch1, are included in the
comparison. Lmo2-clonal tumors have higher class II bHLH
transcription factor expression and lower expression of E2A genes
when compared to normal thymus and tumor 7065. C) This heat
map shows documented Notch1 targets and their expression in the
same tumors. All genes shown are normally up-regulated by Notch1
except for Ebf1, Sfpi1, and Flt3, which are repressed. The Lmo2-
clonal tumors show low expression of Notch1 target genes and
higher expression of genes that are repressed. Tumor 98031 has
higher expression of Hes1 and Il2ra and lower expression of Ebf1,
consistent with a heterozygous mutation in the heterodimerization
domain of Notch1. The rest of the tumors had wild type Notch1
sequences. D) Experimentally confirmed Lmo2-binding partners
are shown on this heat map. All of these were expressed at levels
higher than normal thymus and tumor 7065. The Lmo2-clonal
tumors had high expression of Gata1 and Gata2. Gata1 was very
high in tumor 98031 and so we assayed the expression of erythroid
genes in this tumor. E) Numerous erythroid genes were up-
regulated in 98031. The genes denoted by the black arrows are
activated by an Lmo2/Gata1/2/Tal1/E47/Ldb1-containing
oligomeric complex that binds to promoter E box/Gata-motifs.
Log2 intensity scales are shown for the heat maps.
Found at: doi:10.1371/journal.pgen.1000491.s001 (2.29 MB TIF)
Figure S2 Human T-ALL microarray analysis shows represen-
tation of many CIS in the transcriptional profile of LMO2-
overexpressing patients. Raw data were retrieved from three large
published T-ALL studies and cases were clustered into LMO2-high
expressing and LMO2-low expressing classes. We next sought to
find the most statistically significant genes that clustered with the
LMO2-high group. The studies’ first authors are cited as well as the
platforms used. In parentheses, we show how many probes were
on the chip used. Below this, we show the number of CIS divided
by the total number of genes that clustered with the LMO2-high
expressing cases. The last number is the p value for identifying
these CIS as calculated by Fisher’s exact test.
Found at: doi:10.1371/journal.pgen.1000491.s002 (2.78 MB TIF)
Figure S3 Il2rg insertions are clonal but cause no transcriptional
activation. A) the structure of the genomic region with Il2rg and
Med12 genes is shown. Yellow exons are coding and black arrows
show transcriptional start sites and orientation. Southern analysis
of tumor 7107 was done using NcoI digested tumor DNA. The
germline band is identified by the arrow, G. The rearranged band
is present with equal intensity and shown by the red asterisk. The
size of the NcoI fragment did not allow discrimination between the
two insertions in tumor 7107 since they were so close to each
other. B) Primers were designed for quantitative RT-PCR for Il2rg
and Med12 transcripts. The real time PCR data was normalized to
thymus.
Found at: doi:10.1371/journal.pgen.1000491.s003 (0.59 MB TIF)
Figure S4 Tumor 7107 has one copy of Il2rg and two copies of
Irs2 per cell. A) Primers were designed for a segment of genomic
DNA 59 of the Il2rg gene and used to quantify copy number in
tumor 7107. As control, genomic DNA was prepared from male
and female mouse thymi. Ct values were plotted versus log (ng of
gDNA). Equations and R
2 values of the linear regression models
are shown. Tumor 7107 QPCR shows similar trend to the male
mouse consistent with one Il2rg copy per cell. Standard errors for
each point represent triplicates and the experiment was performed
twice. B) We applied QPCR to the other Lmo2-clonal tumors
which were all female. Genomic DNA from tumor 3095 was
unavailable. Ct values for 98031 were normalized to 1 for relative
quantification. The results confirm that tumor 7107 was not
polyploid for Il2rg gene. Standard errors are shown. Independent
t-test (p=5.3610
25) and Mann-Whitney U-test (p=0.02) both
showed statistically significant difference between tumor 7107 and
the other tumors. This confirms that all the tumors are diploid for
chromosome X except for tumor 7107 which arose in a male
mouse. C) A BAC encompassing the mouse Irs2 gene (chromo-
some 8) was labeled with Spectrum Orange and fluorescent in situ
hybridization (FISH) performed on paraffin-embedded tumor.
The section shown is completely involved with tumor cells and
shows two signals for the labeled probe per cell. We did not find
hyperdiploidy for Irs2 throughout the tumor.
Found at: doi:10.1371/journal.pgen.1000491.s004 (2.16 MB TIF)
Figure S5 Common gamma cytokine pathways are enriched in
human and mouse T-ALL data sets. We combined human gene
expression data with mouse insertion site profiles and performed
Ingenuity pathway analysis. We identified a network of genes that
were upregulated in at least two of the data sets. Statistical analysis
of the Biocarta pathways present in this network is shown. The
Ingenuity network contained 15 genes. List hits indicates how
many of these were present in the specific Biocarta pathway.
Population hits shows how many genes are present in the Biocarta
pathway and Population total shows how many total genes are
present in all of Biocarta at the time of our analysis. P values are
calculated using Fisher’s exact test.
Found at: doi:10.1371/journal.pgen.1000491.s005 (2.81 MB TIF)
Table S1 This table shows a list of genes that are common to
mouse and human leukemias.
Found at: doi:10.1371/journal.pgen.1000491.s006 (0.02 MB
XLS)
Text S1 Supplementary methods and results.
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DOC)
Dataset S1 This is a more comprehensive version of Table 1
which shows common insertion sites as well those insertions that
are not CIS in the Retroviral Tagged Cancer Gene Database. If
the gene has been implicated in human or mouse cancer, then the
associated pathology is shown based on Sanger’s Cancer Gene
Census. Number of clones and frequency indicates how often an
insertion appeared after shotgun cloning. It is calculated as the
total identical clones divided by all informative clones found per
tumor. Higher frequency indicates higher enrichment in the tumor
genomic DNA.
Found at: doi:10.1371/journal.pgen.1000491.s008 (0.04 MB
XLS)
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